<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancerToshiyuki Hirano, Kenzo Soejima, Hiroyuki Yasuda et al.|Oncotarget|2015Cited by 159
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Research|2016Cited by 73
Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer CellsTetsuo Tani, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2015Cited by 63
Prognostic values of the Berlin definition criteria, blood lactate level, and fibroproliferative changes on high-resolution computed tomography in ARDS patientsTetsuro Kamo, Tomoko Betsuyaku|BMC Pulmonary Medicine|2019Cited by 55
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutationsKeita Masuzawa, Tomoko Betsuyaku|Oncotarget|2017Cited by 55